Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00508625
First received: July 26, 2007
Last updated: October 29, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2012
  Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
No publications provided by Amgen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):